Aziz TOKER, Erkan ERKAN, Uğur YÜCETAŞ, Fatma Sinem Hocaoğlu EMRE

eNOS gene polymorphısms and transıtıonal cell cancer of the bladder

Aim: In this case-control study, we examined the association between two types of eNOS gene polymorphisms (intron 4 a/b andGlu298Asp) and transitional cell carcinoma (TCC) of the bladder.Nitric Oxide (NO) is a free radical that plays a key role in various physiological and pathophysiological processes, particularly inthe circulatory system. Endothelial Nitric Oxide Synthase (eNOS), as a member of NOS family, is the enzyme, responsible for thephysiological production of nitric oxide in the endothelium. Polymorphisms of eNOS have been related to increased risk for differenttypes of cancers.Material and Methods: A total of 64 patients with bladder TCC and 80 controls with similar epidemiological characteristics of patientsgroup were evaluated and compared in terms of eNOS gene polymorphisms of two different types ((intron 4 a/b and Glu298Asp).Following DNA isolation from the blood samples, eNOS gene was replicated via PCR. The genomic distribution of two types of eNOSpolymorphism was determined by gel electrophoresis following the process of restriction, for both groups.Results: The alleles most commonly observed in patient group were “ab” for intron 4 (OR= 1.80, 95% CI: 0.71-4.64; P=0.20) and “GT”for Glu298Asp polymorphisms (OR= 1.65, 95% CI: 0.85-3.22; P=0.14). Neither bladder cancer risk nor disease grade was associatedwith these polymorphisms.Conclusions: This study suggests that the intron 4 a/b and Glu298Asp eNOS gene polymorphisms are not associated with bladdercancer susceptibility. However, it is mandatory to conduct further trials with more patients to confim these fidings and to evaluatethe association between bladder cancer and eNOS gene polymorphisms.

PDF

___

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 23/03/2020.
2. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
3. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J. 1994;298:249-58.
4. De Wilt JHW, Manusama ER, van Etten B, et al. Nitric oxide synthase inhibition results in synergistic antitumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer Suppl 2000;83;1176-82.
5. Hussain SP, Trivers GE, Hofseth LJ, et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Research 2004;64:6849-53.
6. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001;98:2604-9.
7. Chhatwal VJ, Ngoi SS, Chan ST, et al. Aberrant expression of nitric oxide synthase in human polyps, neoplastic colonic mucosa and surrounding peritumoral normal mucosa. Carcinogenesis 1994; ;15:2081-5.
8. Reveneau S, Arnould L, Jolimoy G, et al. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest. 1999;79:1215-25.
9. Cobbs CS, Brenman JE, Aldape KD, et al. Expression of Nitric Oxide Synthase in Human Central Nervous System Tumors. Cancer Res 1995;55:727-30.
10. Franco L, Doria D, Bertazzoni E, et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic cancer. Prostaglandins Other Lipid Mediat 2004;73:51-8.
11. Cheon KT, Choi KH, Lee HB, et al. Gene polymorphisms of endothelial nitric oxide synthase and angiotensinconverting enzyme in patients with lung cancer. Lung 2000;178:351-60.
12. Lee KM, Kang D, Park SK, Berndt SI, Reding D, Chatterjee N, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009;30:621-5.
13. Lu J, Wei Q, Bondy ML, et al. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 2006;107:2245-53.
14. Wang XL, Mahaney MC, Sim AS, et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 1997;17:3147-53.
15. Wang XL, Sim AS, Badenhop RF, et al. A smoking dependant risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2:41-5.
16. Tsukada T, Yokoyama K, Arai T, et al. Evidence of Association of the ecNOS Gene Polymorphism with Plasma NO Metabolite Levels in Humans. Biochem Biophys Res Commun1998;245190-3.
17. Erkan E, Toktas G, Unluer E, et al.Expression of NOS isoforms in internal spermatic veins of infertile men with varicocele. Syst Biol Reprod Med. 2012;58:268- 73.
18. Verim L, Toptas B, Ozkan NE, et al. Possible relation between the NOS3 gene GLU298ASP polymorphism and bladder cancer in Turkey. Asian Pac J Cancer Prev 2013;14:665-8.
19. Ryk C, Wiklund NP, Nyberg T, de Verdier PJ. Polymorphisms in nitric-oxide synthase 3 may influence the risk of urinary-bladder cancer. Nitric Oxide 2011;25:338-43.
20. Lembo G, De Luca N, Battagli C, et al. A common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 2001;32:735-40.
21. Huang ZM, Chen HA, Chiang YT, et al. Association of polymorphisms in iNOS and NQO1 with bladder cancer risk in cigarette smokers. J Chin Med Assoc 2014;77:83-8.
22. Ryk C, Wiklund NP, Nyberg T, et al. Ser608Leu polymorphisms in the nitric oxide synthase-2 gene may influence urinary bladder cancer pathogenesis. Scand J Urol Nephrol 2011;45:319-25.
23. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992;107:1092-5.